S
Shehzad Basaria
Researcher at Brigham and Women's Hospital
Publications - 236
Citations - 13294
Shehzad Basaria is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Testosterone (patch) & Androgen deprivation therapy. The author has an hindex of 55, co-authored 226 publications receiving 11446 citations. Previous affiliations of Shehzad Basaria include University of Texas Health Science Center at Houston & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
Mingzhao Xing,William H. Westra,Ralph P. Tufano,Yoram Cohen,Eli Rosenbaum,Kerry J. Rhoden,Kathryn A. Carson,Vasily Vasko,A Larin,Giovanni Tallini,Sara M. Tolaney,Elizabeth H. Holt,Pei Hui,Christopher B. Umbricht,Shehzad Basaria,Marge Ewertz,Anthony P. Tufaro,Joseph A. Califano,Matthew D. Ringel,Martha A. Zeiger,David Sidransky,Paul W. Ladenson +21 more
TL;DR: In patients with PTC, BRAF mutation is associated with poorer clinicopathological outcomes and independently predicts recurrence, and may be a useful molecular marker to assist in risk stratification for patients withPTC.
Journal ArticleDOI
Effects of Testosterone Treatment in Older Men
Peter J. Snyder,Shalender Bhasin,Glenn R. Cunningham,Alvin M. Matsumoto,Alisa J. Stephens-Shields,J. A. Cauley,Thomas M. Gill,Elizabeth Barrett-Connor,Ronald S. Swerdloff,Ronald S. Swerdloff,Christina Wang,Christina Wang,Kristine E. Ensrud,Cora E. Lewis,John T. Farrar,David Cella,Raymond C. Rosen,Marco Pahor,Jill P. Crandall,Mark E. Molitch,Denise Cifelli,Darlene Dougar,Laura Fluharty,Susan M. Resnick,Thomas W. Storer,Stephen D. Anton,Shehzad Basaria,Susan J. Diem,X. Hou,Emile R. Mohler,J. K. Parsons,Nanette K. Wenger,Bret Zeldow,J. R. Landis,Susan S. Ellenberg +34 more
TL;DR: In symptomatic men 65 years of age or older, raising testosterone concentrations for 1 year from moderately low to the mid-normal range for men 19 to 40 years ofAge had a moderate benefit with respect to sexual function and some benefit withrespect to mood and depressive symptoms but no benefit with Respect to vitality or walking distance.
Journal ArticleDOI
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Paul L. Nguyen,Shabbir M.H. Alibhai,Shehzad Basaria,Anthony V. D'Amico,Philip W. Kantoff,Nancy L. Keating,David F. Penson,Derek J. Rosario,Bertrand Tombal,Matthew R. Smith +9 more
TL;DR: ADT is often a necessary component of the treatment of aggressive prostate cancer, yet it has known harms that can impair health and quality of life.
Journal ArticleDOI
Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy
Milena Braga-Basaria,Adrian S. Dobs,Denis C. Muller,Michael A. Carducci,Majnu John,Josephine Egan,Shehzad Basaria +6 more
TL;DR: Data suggest that metabolic syndrome was present in more than 50% of the men undergoing long-term ADT, predisposing them to higher cardiovascular risk.
Journal ArticleDOI
Long-term effects of androgen deprivation therapy in prostate cancer patients
Shehzad Basaria,John Lieb,Alice M. Tang,Theodore L. DeWeese,Michael A. Carducci,Mario A. Eisenberger,Adrian S. Dobs +6 more
TL;DR: Because hypogonadism in men is associated with a wide range of complications, this work attempted to determine the effects of long‐term ADT in men with PCa.